This review is intended d to be a reference to describe the potential. Antimicrobial Efficacy
|
|
- Joel Stephens
- 6 years ago
- Views:
Transcription
1 PRINTER-FRIENDLY VERSION AT PHARMACYPRACTICENEWS.COM Antimicrobial Efficacy JARED L. CRANDON, PHARMD, BCPS Associate Director JOSEPH L. KUTI, PHARMD Associate Director DAVID P. NICOLAU, PHARMD, FCCP, FIDSA Director Center for Anti-Infective e Research and Development Hartford Hospital Hartford, Connecticut This review is intended d to be a reference to describe the potential ti in vivo activity of various antimicrobial agents when the identity of the infecting organism is known. Because the early initiation of appropriate therapy has been noted to improve clinical outcomes for serious infections, empiric therapy frequently demands broad-spectrum antimicrobial agent(s) until the specific infecting bacterium has been identified. Given the continuing concerns of increasing antimicrobial resistance among gram-positive and gram-negative bacteria and the lack of new antibiotics coming to market, knowledge of microbiologic activity and clinical treatment guidelines increases the likelihood of providing appropriate antimicrobial therapy to patients and minimizes the use of unnecessary agents. Importantly, antimicrobial susceptibilities can be highly variable based on institution-specific and geographic factors (including various institutional sites eg, outpatient vs inpatient, intensive care unit vs ward). Therefore, an awareness of local susceptibility data is essential to ensure the highest probability of successful clinical outcomes. While the use of various dosing techniques, especially for β-lactams, may potentiate in vivo activity, the information contained herein pertains only to standard dosing regimens. This review reflects the opinions of the authors and is intended to be a general guide to antimicrobial applications with the appreciation that host factors (eg, site of infection, clinical picture, comorbid conditions) could greatly impact antimicrobial selection. PHARMACY PRACTICE NEWS AUGUST
2 Table 1. Penicillins & Related Antimicrobials Nonantipseudomonal Amoxicillin Ampicillin Penicillin G Penicillin V Ticarcillin Piperacillin Antipseudomonal Ticarcillin-Clavulanate Aztreonam Piperacillin-Tazobactam Imipenem-Cilastatin Meropenem Doripenem Antistaphylococcal Cloxacillin/Dicloxacillin Nafcillin/Oxacillin Amoxicillin-Clavulanate Others Ampicillin-Sulbactam Ertapenem Chlamydia Moraxella catarrhalis Neisseria gonorrhoeae a Neisseria meningitidis Chlamydia pneumoniae (TWAR) Chlamydia psittaci Chlamydia trachomatis Aerobes Other Bacilli (nonenterobacteriaceae) Enterobacteriaceae Coccobacilli Bordetella pertussis Brucella spp. b Campylobacter jejuni Francisella tularensis Helicobacter pylori c 1 Hemophilus ducreyi Hemophilus influenzae d Legionella pneumophila Citrobacter spp. e Enterobacter spp. e,f Escherichia coli f,g Klebsiella pneumoniae f,g Morganella morganii Proteus mirabilis Proteus vulgaris Providencia stuartii Salmonella spp Salmonella typhi Serratia spp Shigella spp Acinetobacter spp. h Burkholderia (Pseudomonas) cepacia h Pseudomonas aeruginosa h Stenotrophomonas (Xanthomonas) maltophilia Pasteurella multocida Vibrio cholerae 3 3 Key to Table First-line agent based on clinical efficacy, susceptibility patterns, and consideration of antimicrobial stewardship and the cost of care. Indicates an alternative drug based on clinical efficacy and susceptibility patterns. Indicates a drug with a low level of activity against this organism, and/or limited clinical efficacy. Either there is insufficient clinical data or this drug should not be used for this organism. 2
3 Table 1. Penicillins & Related Antimicrobials (continued) Nonantipseudomonal Amoxicillin Ampicillin Penicillin G Penicillin V Ticarcillin Piperacillin Antipseudomonal Ticarcillin-Clavulanate Aztreonam Piperacillin-Tazobactam Imipenem-Cilastatin Meropenem Doripenem Antistaphylococcal Cloxacillin/Dicloxacillin Nafcillin/Oxacillin Amoxicillin-Clavulanate Others Ampicillin-Sulbactam Ertapenem Aerobes Anaerobes Bacilli Methicillin-susceptible Staphylococcus epidermidis Methicillin-resistant Staphylococcus epidermidis Streptococcus Group A (S. pyogenes) Streptococcus Group B (S. agalactiae) Streptococcus Group D (eg, S. bovis) Streptococcus pneumoniae i Penicillin-resistant Streptococcus pneumoniae j,k 2 k k 2 Viridans streptococci Actinomycetes Actinomyces israelii Nocardia spp Bacillus anthracis l Corynebacterium diphtheriae m 2 Corynebacterium jeikeium 2 Gardnerella vaginalis n 2 Listeria monocytogenes o Bacteroides fragilis Fusobacterium spp Prevotella melaninogenica Clostridium difficile p Clostridium perfringens Clostridium tetani Peptostreptococcus spp Mycoplasma pneumoniae Ureaplasma urealyticum Borrelia burgdorferi (Lyme disease) q 1 Borrelia recurrenis 2 Leptospira spp Treponema pallidum 1 Myco plasma Spiral Organisms Enterococcus Enterococcus faecalis Vancomycin-resistant Enterococcus faecalis Enterococcus faecium Vancomycin-resistant Enterococcus faecium Methicillin-susceptible Staphylococcus aureus Methicillin-resistant Staphylococcus aureus Glycopeptide-intermediate susceptible Staphylococcus aureus 3
4 Table 2. Aminoglycosides, Macrolides, Quinolones, & Other Antibiotics Aminoglycosides Macrolides Quinolones r Other Antibiotics UTI Agents u Amikacin Gentamicin Streptomycin Tobramycin Azithromycin Clarithromycin Dirithromycin Erythromycin Ciprofloxacin Gemifloxacin Levofloxacin Moxifloxacin Chloramphenicol Clindamycin Colistin/Polymixin B Daptomycin s Fidoxamicin Linezolid Metronidazole Quinupristin-Dalfopristin Rifampin Telavancin Telithromycin Tetracyclines (eg, Doxycycline) t Tigecycline Trimethoprim-Sulfamethoxazole Vancomycin Fosfomycin Nitrofurantoin Norfloxacin Aerobes Aerobes Other Bacilli (Nonenterobacteriaceae) Enterobacteriaceae Coccobacilli Moraxella catarrhalis Neisseria gonorrhoeae a Neisseria meningitidis Chlamydia pneumoniae (TWAR) Chlamydia Chlamydia psittaci Chlamydia trachomatis Bordetella pertussis Brucella spp. b Campylobacter jejuni Francisella tularensis Helicobacter pylori c Hemophilus ducreyi Hemophilus influenzae d Legionella pneumophila Citrobacter spp. e Enterobacter spp. e Escherichia coli f Klebsiella pneumoniae f Morganella morganii Proteus mirabilis Proteus vulgaris Providencia stuartii Salmonella spp Salmonella typhi Serratia spp Shigella spp Acinetobacter spp. g Burkholderia (Pseudomonas) 2 cepacia g Pseudomonas aeruginosa g Stenotrophomonas (Xanthomonas) maltophilia Pasteurella multocida Vibrio cholerae Enterococcus faecalis Vancomycin-resistant Enterococcus Enterococcus faecalis Enterococcus faecium Vancomycin-resistant Enterococcus faecium Staphylococcus aureus Community-associated methicillin-resistant Staphy lococcus aureus v Hospital-associated methicillinresistant Staphylococcus aureus w Glycopeptide-intermediate susceptible Staphylococcus aureus
5 Table 2. Aminoglycosides, Macrolides, Quinolones, & Other Antibiotics (continued) Macrolides Quinolones r Other Antibiotics UTI Agents u Amikacin Gentamicin Streptomycin Tobramycin Azithromycin Clarithromycin Dirithromycin Erythromycin Ciprofloxacin Gemifloxacin Levofloxacin Moxifloxacin Chloramphenicol Clindamycin Colistin/Polymixin B Daptomycin s Fidoxamicin Linezolid Metronidazole Quinupristin-Dalfopristin Rifampin Telavancin Telithromycin Tetracyclines (eg, Doxycycline) t Tigecycline Trimethoprim-Sulfamethoxazole Vancomycin Fosfomycin Nitrofurantoin Norfloxacin Aerobes Anaerobes Bacilli Staphylococcus epidermidis Methicillin-resistant Staphylococcus epidermidis Streptococcus Group A (S. pyogenes) Streptococcus Group B (S. agalactiae) Streptococcus Group D (eg, S. bovis) 2 2 Streptococcus pneumoniae i Penicillin-resistant Streptococcus pneumoniae j,k Viridans streptococci Actinomycetes Actinomyces israelii Nocardia spp Bacillus anthracis l Corynebacterium diphtheriae m Corynebacterium jeikeium Gardnerella vaginalis n Listeria monocytogenes o Bacteroides fragilis Fusobacterium spp Mycoplasma Spiral Organisms Aminoglycosides Prevotella melaninogenica Clostridium difficile p Clostridium perfringens Clostridium tetani Peptostreptococcus spp Mycoplasma pneumoniae Ureaplasma urealyticum Borrelia burgdorferi q Borrelia recurrentis (Lyme disease) 2 Leptospira spp. 2 Treponema pallidum
6 Table 3. Cephalosporins Generations 1st 2nd 3rd 4th Anti- MRSA Aerobes Aerobes Anaerobes Cefadroxil Cefazolin Cephalexin Cefaclor Coccobacilli Enterobacteriaceae Bacilli Moraxella catarrhalis Neisseria gonorrhoeae a Neisseria meningitidis Chlamydia pneumoniae (TWAR) Chlamydia Chlamydia psittaci Chlamydia trachomatis Bordetella pertussis Brucella spp. b Campylobacter jejuni Francisella tularensis Helicobacter pylori c Hemophilus ducreyi Hemophilus influenzae d Legionella pneumophila Citrobacter spp. e Enterobacter spp. e,f Escherichia coli f,g Klebsiella spp.,g Morganella morganii Proteus mirabilis Proteus vulgaris Providencia stuartii Salmonella spp Salmonella typhi 1 1 Serratia spp Shigella spp Acinetobacter spp. h Burkholderia (Pseudomonas) cepacia h 3 3 Pseudomonas aeruginosa h 1 1 Stenotrophomonas (Xanthomonas) maltophilia 3 Pasteurella multocida Vibrio cholerae Enterococcus faecalis Enterococcus Vancomycin-resistant Enterococcus faecalis Enterococcus faecium Vancomycin-resistant Enterococcus faecium Methicillin-susceptible Staphylococcus aureus Methicillin-resistant Staphylococcus aureus 2 Glycopeptide-intermediate susceptible Staphylococcus aureus 1 Methicillin-susceptible Staphylococcus epidermidis Methicillin-resistant Staphylococcus epidermidis 2 Streptococcus Group A (S. pyogenes) Streptococcus Group B (S. agalactiae) Streptococcus Group D (eg, S. bovis) Streptococcus pneumoniae i Penicillin-resistant Streptococcus pneumoniae j,k 2 x 2 x 2 2 Viridans streptococci Actinomycetes Actinomyces israelii Nocardia spp Bacillus anthracis l Corynebacterium diphtheriae m Corynebacterium jeikeium Gardnerella vaginalis n Listeria monocytogenes o Bacteroides fragilis Fusobacterium spp Prevotella melaninogenica Clostridium difficile p Clostridium perfringens Clostridium tetani Peptostreptococcus spp Myco plasma Mycoplasma pneumoniae Ureaplasma urealyticum Borrelia burgdorferi (Lyme disease) q Spiral Borrelia recurrentis Organisms Leptospira spp. Treponema pallidum 2 2 Cefotetan Cefoxitin Cefprozil Cefuroxime Cefdinir Cefditoren Cefotaxime Cefpodoxime Ceftazidime Ceftibuten Ceftizoxime Ceftriaxone Cefepime Ceftaroline Other Bacilli (Nonenterobacteriaceae) 6
7 Notes to Chart a Resistance to penicillin, tetra cycline, and ciproflox acin may be as high as 21.5%, 29.2%, and 47.7%, respectively, according to a 2006 report; 50% of patients have Chlamydia trachomatis. b Use a combination: for example, doxycycline with gentamicin or rifampin or doxycycline with trimethoprim-sulfamethoxazole and chloramphenicol. c Combination therapy with high eradication rates includes omeprazole + clarithromycin + amoxicillin; or bismuth sub salicylate + metro nidazole + tetracycline. However, metro nidazole resistance has risen significantly. d Up to 30% of Haemophilus influenzae strains are capable of producing β-lactamases. e Citrobacter spp. and Enterobacter spp. may differ in susceptibility patterns. Consult individual test results for appropriate choice. f Carbapenemase-producing Enterobacteriaceae are increasing, and are endemic in certain geographic regions. Viable treatment options are limited and should be based on susceptibilities. Generally, colistin/polymixin B and tigecycline offer in vitro susceptibility, although clinical data are limited. Combination therapy is encouraged. g A significant number of strains are capable of producing extended-spectrum β-lactamases (ESBL). Consider this possibility according to antibiogram, patient s history, and local resistance patterns. In suspected or proven cases, use carbapenems or proper non β-lactam antibiotics based on susceptibility studies. h Combination therapy is suggested. i In 2005, the penicillin resistance rate in the United States was reported to be approximately 34%; 10% to 15% of isolates displayed high-level penicillin resistance (MIC [minimum inhibitory concentration] >1 mcg/ml). The Centers for Disease Control and Prevention Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group recommends MIC 4 mcg/ml for high-level resistance. The clinical significance of penicillin resistance in nonbacteremic patients is still uncertain when parenteral treatments are used. j PRSP (penicillin-resistant Streptococcus pneumoniae) being defined as nonsusceptible to penicillin (PCN [penicillin] MIC 2 mcg/ml). k Amoxicillin doses of 80 mg/kg/d may be effective against nonmeningeal RSP infections. l For updates, see hottopics/bioterrorism.html. m Membranous pharyngitis treated with antitoxin and IV erythromycin (antimicrobials used to decrease toxin production and bacterial spread). n New classification: bacteria are gram-variable. o Aminoglycosides (gentamicin) may be synergistic with β-lactams. p Gastroenteritis is treated with only oral formulations of vancomycin. Vancomycin is recommended as first-line therapy for patients with severe illness, while metronidazole is recommended for patients with mild to moderate disease. Fidaxomicin was non-inferior to oral vancomycin in treating CDI, but it was superior in preventing recurrences of non-nap1/ BI/027 strains. q Stage of disease determines choice of treatment. Consult specific references. r Resistance rates can vary greatly against P. aeruginosa, Acinetobacter spp., and the Enterobacteriaceae. Use as empiric therapy against these organisms should be based on local susceptibilities. s Despite its potent in vitro activity against Streptococcus pneumoniae, daptomycin is not indicated for the treatment of pneumonia, due to extensive binding to pulmonary surfactant resulting in clinical failure. t The specific tetracycline recommended varies. For methicillin-resistant Staphylococcus aureus, minocycline is most active among class. Consult specific references. u These agents are generally recommended for urinary tract infections (UTIs) only. Use of the 1 to 3 scale refers to activity for treatment of UTI. v Vancomycin is considered first-line when intravenous therapy is required. However, ceftaroline, daptomycin, linezolid, telavancin, and tigecycline may be suitable alternatives in specified patients. Tetracyclines, clindamycin, trimethoprim-sulfamethoxazole, macrolides, and linezolid are viable alternatives when oral therapy can be used. In the face of erythromycin resistance, clindamycin should be considered only if the isolate is D-test negative. w Vancomycin is considered first-line when IV therapy is required. Notably, in recent years vancomycin MICs have gradually increased for S. aureus and have included an increased occurrence of heteroresistance. Clinical reports have associated this loss of in vitro potency with vancomycin clinical failures in a number of patients. Alternative therapies such as ceftaroline, daptomycin, linezolid, telavancin, and tigecycline should be considered in the appropriate clinical setting. Consult specific references. x Effective choice for meningeal infections if the ceftriax one/cefotaxime MIC <0.5 mcg/ml. 7
8 Suggested Reading Brook I. Management of anaerobic infection. Expert Rev Anti Infect Ther. 2004;2(1): Chow JW, Satishchandran V, Snyder TA, Harvey CM, Friedland IR, Dinubile MJ. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt). 2005(4);6: Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in Antimicrob Agents Chemother. 2003(5);47: Curran M, Simpson D, Perry C. Ertapenem: a review of its use in the management of bacterial infections. Drugs. 2003;63(17): Ferrara AM. Potentially multidrug-resistant nonfermentative gramnegative pathogens causing nosocomial pneumonia. Int J Antimicrob Agents. 2006;27(3): Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2003;46(4): Hansen GT, Blondeau JM. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levo floxacin and garenoxacin against enteric gram-negative urinary tract infection pathogens. J Chemother. 2005;17(5): Kuti JL, Florea NR, Nightingale CH, Nicolau DP. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Pharmacotherapy. 2004;24(1):8-15. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of North America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother. 2003;S1(suppl 2):ii9-ii16. Martin SI, Kaye KM. Beta-lactam antibiotics: newer formulations and newer agents. Infect Dis Clin North Am. 2004;18(3): Nicolau DP. Spotlight on Clostridium difficile infection: an educational resource for pharmacists. Pharmacy Times. 2009;2: Nguyen M, Chung EP. Telithromycin: the first ketolide antimicrobial. Clin Ther. 2005;27(8): Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase producing bacteria. Lancet Infect Dis. 2009;9(4): Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microb Rev. 2005;18(4): Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother. 2002;46(4): Pfaller MA, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Clin Infect Dis. 2006; 42(suppl 4):S153-S163. Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Comparative antimicrobial potency of meropenem tested against gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J Chemother. 2005;17(8): Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Med. 2006;119(6 suppl 1):S11-S19; discussion S62-S70. Roberts S, Chambers S. Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue. Intern Med J. 2005;35 (suppl 2):S97-S105. Torres-Viera C, Dembry LM. Approaches to vancomycin-resistant enterococci. Curr Opin Infect Dis. 2004;17(6): Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs. 2006;66(8): Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin Microbiol Infect. 2005;11(4): Erratum in: Clin Microbiol Infect. 2005;11(6):513. Yamaguchi T, Hashikita G, Takahashi S, Itabashi A, Yamazaki T, Maesaki S. In vitro activity of beta-lactams, macrolides, telithromycin, and fluoroquinolones against clinical isolates of Streptococcus pneumoniae: correlation between drug resistance and genetic characteristics. J Infect Chemother. 2005;11(5): Zhanel GG, Hisanaga TL, Laing NM, et al; NAUTICA Group. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2005;26(5): Dr. Crandon reports no relevant conflicts of interest. Dr. Kuti has received research funding from and/or is on the speaker s bureau and/or advisory board for Astellas, BioMerieux USA, Forest, Merck, Ortho-McNeil, and Pfizer. Dr. Nicolau has received research funding from and/or is on the speaker s bureau and/or advisory board for AstraZeneca, Cerexa, Cubist, Forest, Johnson & Johnson, Merck, Ortho-McNeil, Pfizer, Rib-X, Tetraphase, and Vertex. Visit pharmacypracticenews.com Scan for commentary for a commentary on Implementing an Antimicrobial Stewardship Program by Steve Martin, PharmD, BCPS, FCCM, Chair of the Department of Pharmacy Practice at the University of Toledo College of Pharmacy 8
Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationPrinciples of Antibiotics Use & Spectrum of Some
Principles of Antibiotics Use & Spectrum of Some Rabee Adwan. MD Infectious Diseases Consultant (Pediatric and Adult) Head Of ID Unit and IPAC Committee- AL-Makassed Hospital-AlQuds Head of IPAC Committee
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationBactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261
More informationInfectious Disease: Drug Resistance Pattern in New Mexico
Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationAntimicrobial susceptibility testing challenges. Linda Joyce St Vincent s Hospital Melbourne
Antimicrobial susceptibility testing challenges Linda Joyce St Vincent s Hospital Melbourne Bacteria/antimicrobials without breakpoints (B.A.W.B.S.) Enterobacteriacae Pseudomonas aeruginosa, Acinetobacter
More informationBSAC standardized disc susceptibility testing method (version 8)
Journal of Antimicrobial Chemotherapy (2009) 64, 454 489 doi:10.1093/jac/dkp244 Advance Access publication 8 July 2009 BSAC standardized disc susceptibility testing method (version 8) J. M. Andrews* for
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationQUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)
Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),
More informationBritish Society for Antimicrobial Chemotherapy
British Society for Antimicrobial Chemotherapy BSAC to actively support the EUCAST Disc Diffusion Method for Antimicrobial Susceptibility Testing in preference to the current BSAC Disc Diffusion Method
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationBritish Society for Antimicrobial Chemotherapy
British Society for Antimicrobial Chemotherapy Standing Committee on Susceptibility Testing Version 13.0, 10-06-2014 Content Page Additional information Changes in version 13 2 Suggestions for appropriate
More informationHUSRES Annual Report 2007 Martti Vaara.
HUSRES Annual Report 2007 Martti Vaara www.huslab.fi www.intra.hus.fi The basis of this HUSRES 2007 report is the HUSLAB/Whonet database 2007, which contains susceptibility data on about 182.000 bacteria
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationEUCAST-and CLSI potency NEO-SENSITABS
EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationPenicillins - EUCAST clinical MIC breakpoints (version 1.3)
EUCAST clinical MIC breakpoints - penicillins Penicillins - EUCAST clinical MIC breakpoints 2009-04-19 (version 1.3) Penicillins Click on antibiotic name to see wild type MIC distributions. Enterobacteriaceae
More informationAntimicrobials. Antimicrobials
Antimicrobials For more than 50 years, antibiotics have come to the rescue by routinely producing rapid and long-lasting miracle cures. However, from the beginning antibiotics have selected for resistance
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationAntimicrobial Agents 101. SWACM 2011 Christopher Doern, Ph.D., D(ABMM)
Antimicrobial Agents 101 SWACM 2011 Christopher Doern, Ph.D., D(ABMM) β -Lactams Penicillins Cephalosporins Carbapenems Monobactams β -Lactamase Inhibitors Clavulanate Amox/Clav Ticar/Clav Sulbactam Amp/Sulb
More informationFundamental Concepts in the Use of Antibiotics. Case. Case. TM is a 24 year old male admitted to ICU after TBI and leg fracture from MVA ICU day 3
Fundamental Concepts in the Use of Antibiotics Todd Miano, PharmD, MSCE Critical Care Pharmacist Pharmacoepidemiology Fellow Perelman School of Medicine at the University of Pennsylvania Case TM is a 24
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationAntimicrobial Resistance Trends in the Province of British Columbia
655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2443 Fax 604.707.2441 www.bccdc.ca Antimicrobial Resistance Trends in the Province of British Columbia 2013 Prepared by the Do Bugs Need Drugs? Program
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationReceived: February 29, 2008 Revised: July 22, 2008 Accepted: August 4, 2008
J Microbiol Immunol Infect. 29;42:317-323 In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center
More informationFluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do?
Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More informationLeveraging the Lab and Microbiology Department to Optimize Stewardship
Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center
More informationPathogens commonly isolated from selected diseases
Pathogens commonly isolated from selected diseases Equine pneumonia/pleuropneumonia -hemolytic Strep. Clostridium Pasteurella E. coli Klebsiella pneumoniae Bacteroides Equine enteric pathogens Salmonella
More informationIV Antibiotics for Lyme Disease (Ceftriaxone, Cefotaxime sodium, Doxycycline, Penicillin G potassium)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.15 Subject: IV Antibiotics Lyme Disease Page: 1 of 9 Last Review Date: November 30, 2018 IV Antibiotics
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationCleaning and Disinfection Protocol Vegetative Bacteria
Cleaning and Disinfection Protocol Vegetative Bacteria This document has been developed in accordance with current applicable infection control and biosecurity guidelines. It is intended for use as a guideline
More informationAntimicrobial Susceptibility Summary 2011
Antimicrobial Susceptibility Summary 2011 Clinical Microbiology Department of Pathology & Laboratory Medicine 45 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and Laboratory
More informationEAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia
EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia Background The Expert Advisory Group on Antimicrobial Resistance of the NH&MRC provides advice to Australian governments and
More informationMike Apley Kansas State University
Mike Apley Kansas State University 2003 - Daptomycin cyclic lipopeptides 2000 - Linezolid - oxazolidinones 1985 Imipenem - carbapenems 1978 - Norfloxacin - fluoroquinolones 1970 Cephalexin - cephalosporins
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationTABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11
Policy #MI\ANTI\v23 Page 1 of 3 Section: Antimicrobial Susceptibility Testing Subject Title: Table of Contents Manual Issued by: LABORATORY MANAGER Original Date: January 10, 2000 Approved by: Laboratory
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationSuper Bugs and Wonder Drugs: Protecting the One While Respecting the Many
Super Bugs and Wonder Drugs: Protecting the One While Respecting the Many Vicki Stringfellow, MSN, CPNP-AC/PC Werner Division of Pediatric Critical Care University of Kentucky Lexington, KY Disclosure
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationCleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria
Cleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria This document has been developed in accordance with current applicable infection
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationAMR Industry Alliance Antibiotic Discharge Targets
AMR Industry Alliance Antibiotic Discharge Targets List of Predicted No-Effect Concentrations (PNECs) The members of the AMR Industry Alliance have developed a unified approach to establishing discharge
More informationEDUCATIONAL COMMENTARY A PRIMER IN ANTIBIOTICS FOR THE LABORATORY PROFESSIONAL
Linsey Donner, MPH, CPH, MLS (ASCP) CM Assistant Professor, Microbiology and Serology College of Allied Health Professions, Division of Medical Laboratory Science University of Nebraska Medical Center
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More information